(F.No. 37001/2020/Div.III/NPPA)

Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals National Pharmaceuticals Pricing Authority

5th /3rd Floor, YMCA Cultural Centre Building, 1, Jai Singh Road, New Delhi-110001 Date the **27**th **March**, 2020

ORDER

In exercise of powers given under Paragraph 29- 'Maintenance of records and production thereof for inspection" of The Drugs (Prices Control) Order, 2013, the drug manufacturers of medicines namely FDC Lopinavir and Ritonavir (200MG +50 MG), Hydroxychloroquine 200 MG & 400 MG, Azithromycin 250 MG & 500 MG and Paracetamol 500mg hereby directed, in order to deal with the situation arising out of COVID-19, to submit the information as per attached Performa by 6.00 PM today.

2. This issues with approval of competent authority.

(S. S. Ojha) Director (Pricing)

To,

Drug Manufacturers:- For compliance of direction given above.

Copy for information to:-

- 1. PSO to Secretary (Pharma)
- 2. Sr. PPS to Secretary (Health)
- 3. Sr. PPS to Chairman, NPPA
- 4. PPS to JS (Policy), Deptt. of Pharmaceuticals
- 5. Dr. S. Eswara Reddy, Joint Drugs Controller General of India

Details of availability of identified formulations

		SNO
	Company	Nomoof
	Installed Capacity Tablets per day	
	Total Stock in hand in number of Tablets	
	Domestic Commitment in number of Tablets	
	Current stock of API in KG	
imported from 15 th	If API/KSM is imported, how much quantity	
increased, if rerquired	How much additional capacity can be	
	5± C	Company Capacity Tablets per day Total Stock Commitment Commitment Total Stock Commitment For exports In number of day Total Stock Commitment For exports In number of day Total Stock Total Stock Tommitment For exports In number of day Tablets Tablets Tablets Total Stock Commitment For exports In number of day Tablets Tablets Tablets Total Stock Commitment Commitment Stock of API Is imported, how much quantity imported from 15 th